( GAITHERSBURG Md.--(BUSINESS WIRE)--May...)GenVec Presents Research on New Ad35 Adenovector at ARVO,Health

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 - GenVec, Inc. (Nasdaq:GNVC) today announced pre-clinical research demonstrating the ability of the Company's new adenovector, Ad35, to induce and sustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec's Director of Pre-Clinical Research, presented a poster, Alternate Serotype Adenovector Gives Long-Term Expression in the Eye, at the Association for Research in Vision and Ophthalmology ("ARVO") Annual Meeting in Fort Lauderdale, Florida.

Currently available treatments for ocular neovascular diseases such as wet age-related macular degeneration (AMD) involve intravitreal injections to the eye. Both patients and doctors desire less frequent injections into the eye to deliver such therapeutics. A possible strategy is the use of gene delivery systems to achieve sustained production of therapeutic proteins in the eye over a period of several months.

GenVec researchers compared the duration of expression in the eye of two different adenovectors, Ad5 and Ad35. The results showed sustained protein expression beyond 4 months in eyes treated with the Ad35 vector. With the Ad5 vector, expression diminished substantially by day 7. These results indicate that changes in the adenovector can lead to potentially important advantages in the delivery of proteins. In the case of AMD, less frequent drug administration would be of clear benefit to patients.

"It is now clear that delivery of anti-angiogenic agents to the eye can be effective in treating AMD by blocking abnormal blood vessel formation," stated Dr. Wei. "Our studies reported today demonstrated delivery of PEDF, a potent factor capable of both blocking and reversing animal models of AMD. We believe that sustained delivery of other therapeutic proteins to the eye should be possible using this technology."

About AMD

AMD affects almost thirty percent of adults between the ages of 75 an
'"/>

Page: 1 2 3
Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting